What is Atea Pharmaceuticals, Inc.'s earnings per share (EPS)?

Atea Pharmaceuticals, Inc. (AVIR) reported diluted earnings per share of -$1.94 for fiscal year 2025. This represents a 3.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atea Pharmaceuticals, Inc. Financials

AVIR

FY2025 annual

Revenue Not reported for FY2025

Net Income -$158.0M +6.0% YoY

EPS (Diluted) -$1.94 +3.0% YoY

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

This page shows Atea Pharmaceuticals, Inc. (AVIR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AVIR FY2025 2026-08-12

Asset reshuffling, not operations, kept cash higher in FY2025 while research spending remained the main driver of losses.

In FY2025, cash ended at $95.7M even as operating cash flow was -$132.0M. That was made possible by an investing inflow of $188.8M while total assets fell to $315.2M, so liquidity came from converting existing assets into cash rather than from making the business less cash-intensive.

The cost base is still research-led: FY2025 R&D of $148.0M was more than four times SG&A of $32.9M. Because R&D also stayed above FY2024's $144.1M while SG&A fell from $48.8M, the smaller operating loss points to leaner overhead, not to reduced development activity.

The balance sheet remains lightly obligated, with total liabilities of $39.8M against equity of $275.4M. But cash consumption still dominates the story: FY2025 operating cash flow of -$132.0M was larger than year-end cash of $95.7M, so the economic pressure comes from sustaining the research program rather than from debt service.

Financial Health Signals

Financial health score not available

Atea Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Atea Pharmaceuticals, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Atea Pharmaceuticals, Inc. reported a net loss of $158.0M while operations used $132.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$180.5M

YoY+6.3%

Atea Pharmaceuticals, Inc.'s EBITDA was -$180.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.3% from the prior year.

Net Income

-$158.0M

YoY+6.0%

Atea Pharmaceuticals, Inc. reported -$158.0M in net income in fiscal year 2025. This represents an increase of 6.0% from the prior year.

EPS (Diluted)

-$1.94

YoY+3.0%

Atea Pharmaceuticals, Inc. earned -$1.94 per diluted share (EPS) in fiscal year 2025. This represents an increase of 3.0% from the prior year.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$95.7M

YoY+47.9%

5Y CAGR-35.4%

Atea Pharmaceuticals, Inc. held $95.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

78M

YoY-7.5%

Atea Pharmaceuticals, Inc. had 78M shares outstanding in fiscal year 2025. This represents a decrease of 7.5% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-57.4%

YoY-19.1pp

5Y CAGR-55.4pp

Atea Pharmaceuticals, Inc.'s ROE was -57.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 19.1 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$148.0M

YoY+2.7%

5Y CAGR+31.2%

Atea Pharmaceuticals, Inc. invested $148.0M in research and development in fiscal year 2025. This represents an increase of 2.7% from the prior year.

Share Buybacks

$25.5M

Atea Pharmaceuticals, Inc. spent $25.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

Not reported for fiscal year 2025.

AVIR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AVIR annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Revenue	N/A	N/A	N/A	N/A	N/A	$351.4M+622.5%	$48.6M	N/A	N/A
R&D Expenses	N/A	$148.0M+2.7%	$144.1M+26.1%	$114.2M+39.4%	$81.9M-51.0%	$167.2M+339.7%	$38.0M+273.9%	$10.2M+52.4%	$6.7M
SG&A Expenses	N/A	$32.9M-32.7%	$48.8M-2.1%	$49.9M+2.5%	$48.7M+6.4%	$45.8M+111.6%	$21.6M+387.6%	$4.4M+58.4%	$2.8M
Operating Income	N/A	-$180.9M+6.3%	-$192.9M-17.5%	-$164.2M-25.7%	-$130.7M-194.4%	$138.4M+1354.6%	-$11.0M+24.5%	-$14.6M-54.1%	-$9.5M
Income Tax	N/A	-$6.2M-766.2%	$925K-9.1%	$1.0M+128.4%	-$3.6M-120.6%	$17.4M	N/A	N/A	N/A
Net Income	N/A	-$158.0M+6.0%	-$168.0M-23.5%	-$136.0M-17.2%	-$116.0M-195.9%	$121.0M+1205.3%	-$10.9M+22.0%	-$14.0M-54.8%	-$9.1M
EPS (Diluted)	—	-$1.94+3.0%	-$2.00-22.7%	-$1.63-17.3%	-$1.39-201.5%	$1.37	-$0.51	-$1.39	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$28.1M-31.6%	$41.1M	N/A	$38.3M+18.8%	$32.3M+9.1%	$29.6M	N/A	$26.2M
SG&A Expenses	$6.9M+1.1%	$6.9M	N/A	$7.2M-20.4%	$9.1M-4.1%	$9.5M	N/A	$11.0M
Operating Income	-$35.1M+26.9%	-$48.0M	N/A	-$45.6M-10.2%	-$41.3M-5.9%	-$39.0M	N/A	-$37.2M
Income Tax	$24K-52.0%	$50K	N/A	$196K-5.3%	$207K+2.0%	$203K	N/A	$226K
Net Income	-$32.9M+27.5%	-$45.4M	N/A	-$42.0M-13.2%	-$37.2M-8.4%	-$34.3M	N/A	-$31.2M
EPS (Diluted)	-$0.41+28.1%	-$0.57	N/A	-$0.53-20.5%	-$0.44-10.0%	-$0.40	N/A	-$0.37

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

AVIR Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AVIR annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Total Assets	$315.2M-32.2%	$464.7M-21.9%	$595.0M-10.8%	$666.7M-13.7%	$772.9M-10.5%	$863.6M+3812.6%	$22.1M	N/A
Current Assets	$311.0M-32.7%	$462.4M-21.7%	$590.5M-10.7%	$660.9M-14.4%	$772.4M-10.5%	$863.5M+3841.0%	$21.9M	N/A
Cash & Equivalents	$95.7M+47.9%	$64.7M-55.0%	$143.8M-23.7%	$188.5M-75.3%	$764.4M-10.1%	$850.1M+3824.6%	$21.7M-37.2%	$34.5M
Total Liabilities	$39.8M+54.2%	$25.8M-35.1%	$39.8M+52.2%	$26.1M-58.4%	$62.8M-80.1%	$315.8M+340.8%	$71.6M	N/A
Current Liabilities	$39.8M+113.9%	$18.6M-42.5%	$32.4M+75.2%	$18.5M-67.5%	$56.9M-82.0%	$315.8M+12869.0%	$2.4M	N/A
Total Equity	$275.4M-37.2%	$438.9M-21.0%	$555.2M-13.3%	$640.6M-9.8%	$710.1M+29.6%	$547.8M+1205.1%	-$49.6M-37.1%	-$36.2M
Retained Earnings	-$522.6M-43.5%	-$364.2M-86.0%	-$195.8M-227.1%	-$59.9M-206.9%	$56.0M+186.0%	-$65.2M-20.2%	-$54.2M	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$232.3M-13.0%	$267.1M-15.3%	$315.2M-8.1%	$343.0M-12.4%	$391.6M-11.0%	$440.0M-5.3%	$464.7M-5.4%	$491.0M
Current Assets	$228.7M-13.1%	$263.2M-15.4%	$311.0M-7.5%	$336.1M-12.8%	$385.6M-11.1%	$433.7M-6.2%	$462.4M-5.0%	$486.9M
Cash & Equivalents	$76.5M-3.5%	$79.3M-17.1%	$95.7M+23.7%	$77.3M-11.8%	$87.7M-26.5%	$119.4M+84.5%	$64.7M-34.3%	$98.5M
Total Liabilities	$28.1M-15.7%	$33.4M-16.1%	$39.8M+46.4%	$27.2M0.0%	$27.2M-5.9%	$28.9M+11.9%	$25.8M-20.5%	$32.4M
Current Liabilities	$28.1M-15.7%	$33.4M-16.1%	$39.8M+97.2%	$20.2M+0.3%	$20.1M-7.5%	$21.7M+16.9%	$18.6M-26.1%	$25.2M
Total Equity	$204.2M-12.6%	$233.7M-15.1%	$275.4M-12.8%	$315.8M-13.3%	$364.4M-11.4%	$411.1M-6.3%	$438.9M-4.3%	$458.5M
Retained Earnings	-$600.9M-5.8%	-$568.0M-8.7%	-$522.6M-9.4%	-$477.7M-9.7%	-$435.7M-9.3%	-$398.5M-9.4%	-$364.2M-10.1%	-$330.7M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

AVIR Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AVIR annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Operating Cash Flow	-$152.1M	-$132.0M+2.6%	-$135.5M-58.7%	-$85.4M+29.4%	-$121.0M-39.1%	-$87.0M-129.3%	$296.7M+2413.0%	-$12.8M-62.2%	-$7.9M
Capital Expenditures	N/A	N/A	N/A	N/A	$1.9M+48475.0%	$4K-84.6%	$26K+1200.0%	$2K-83.3%	$12K
Free Cash Flow	N/A	N/A	N/A	N/A	-$122.9M-41.3%	-$87.0M-129.3%	$296.7M+2412.4%	-$12.8M-62.0%	-$7.9M
Investing Cash Flow	$151.9M	$188.8M+236.5%	$56.1M+39.2%	$40.3M+108.8%	-$455.4M-11385150.0%	-$4K+84.6%	-$26K-1200.0%	-$2K+83.3%	-$12K
Financing Cash Flow	-$11.0M	-$25.7M-9742.3%	$267K+3.9%	$257K-30.5%	$370K-74.7%	$1.5M-99.7%	$531.7M	N/A	$27.5M
Share Buybacks	N/A	$25.5M	$0	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$37.1M+20.1%	-$46.4M-64.4%	-$28.2M+30.1%	-$40.4M-22.8%	-$32.9M-7.5%	-$30.6M-0.5%	-$30.4M-32.0%	-$23.0M
Investing Cash Flow	$34.3M+15.4%	$29.7M-36.2%	$46.6M+12.8%	$41.3M+170.1%	$15.3M-82.1%	$85.6M+2640.3%	-$3.4M+97.2%	-$122.0M
Financing Cash Flow	$0-100.0%	$257K	$0+100.0%	-$11.3M+19.8%	-$14.1M-3961.4%	-$347K	$0-100.0%	$117K
Share Buybacks	N/A	N/A	$0-100.0%	$11.4M	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid.

AVIR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

AVIR annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Operating Margin	N/A	N/A	N/A	N/A	39.4%+62.1pp	-22.7%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	34.4%+57.0pp	-22.5%	N/A	N/A
Return on Equity	-57.4%-19.1pp	-38.3%-13.8pp	-24.5%-6.4pp	-18.1%-35.2pp	17.0%+19.0pp	-2.0%	N/A	N/A
Return on Assets	-50.1%-14.0pp	-36.1%-13.3pp	-22.9%-5.5pp	-17.4%-33.1pp	15.7%+16.9pp	-1.3%+62.3pp	-63.6%	N/A
Current Ratio	7.82-17.0x	24.85+6.6x	18.24-17.5x	35.77+22.2x	13.58+10.8x	2.73-6.3x	9.00	N/A
Debt-to-Equity	0.14+0.1x	0.060.0x	0.070.0x	0.040.0x	0.09-0.5x	0.58	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	-24.8%	610.1%	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-16.1%+3.3pp	-19.4%	N/A	-13.3%-3.1pp	-10.2%-1.9pp	-8.3%	N/A	-6.8%
Return on Assets	-14.2%+2.8pp	-17.0%	N/A	-12.3%-2.8pp	-9.5%-1.7pp	-7.8%	N/A	-6.3%
Current Ratio	8.13+0.2x	7.89+0.1x	7.82-8.8x	16.66-2.5x	19.17-0.8x	19.94-4.9x	24.85+5.5x	19.33
Debt-to-Equity	0.140.0x	0.140.0x	0.14+0.1x	0.090.0x	0.070.0x	0.070.0x	0.060.0x	0.07

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: FCF Margin.

Similar Companies

Neumora Therapeutics Inc NMRA

$308.1M

Omeros OMER

$1.3B

Candel Therapeutics, Inc. CADL

$1.0B

Rapt Therapeutics, Inc. RAPT

$1.7B

Invivyd IVVD

$282.8M

Where Atea Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. profitable?

No, Atea Pharmaceuticals, Inc. (AVIR) reported a net income of -$158.0M in fiscal year 2025.

What is Atea Pharmaceuticals, Inc.'s EBITDA?

Atea Pharmaceuticals, Inc. (AVIR) had EBITDA of -$180.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Atea Pharmaceuticals, Inc.'s return on equity (ROE)?

Atea Pharmaceuticals, Inc. (AVIR) has a return on equity of -57.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Atea Pharmaceuticals, Inc.'s operating cash flow?

Atea Pharmaceuticals, Inc. (AVIR) recorded an outflow of $132.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Atea Pharmaceuticals, Inc.'s total assets?

Atea Pharmaceuticals, Inc. (AVIR) had $315.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Atea Pharmaceuticals, Inc. spend on research and development?

Atea Pharmaceuticals, Inc. (AVIR) invested $148.0M in research and development during fiscal year 2025.

Does Atea Pharmaceuticals, Inc. buy back shares?

Yes, Atea Pharmaceuticals, Inc. (AVIR) spent $25.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Atea Pharmaceuticals, Inc. have outstanding?

Atea Pharmaceuticals, Inc. (AVIR) had 78M shares outstanding as of fiscal year 2025.

What is Atea Pharmaceuticals, Inc.'s current ratio?

Atea Pharmaceuticals, Inc. (AVIR) had a current ratio of 7.82 as of fiscal year 2025, which is generally considered healthy.

What is Atea Pharmaceuticals, Inc.'s debt-to-equity ratio?

Atea Pharmaceuticals, Inc. (AVIR) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Atea Pharmaceuticals, Inc.'s return on assets (ROA)?

Atea Pharmaceuticals, Inc. (AVIR) had a return on assets of -50.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Atea Pharmaceuticals, Inc.'s cash runway?

Based on fiscal year 2025 data, Atea Pharmaceuticals, Inc. (AVIR) had $95.7M in cash against an annual operating cash burn of $132.0M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Atea Pharmaceuticals, Inc.'s Piotroski F-Score?

Atea Pharmaceuticals, Inc. (AVIR) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Atea Pharmaceuticals, Inc.'s earnings high quality?

Atea Pharmaceuticals, Inc. (AVIR) reported a net loss of $158.0M while operations used $132.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.